All In Biotech

Free tool

FAERS Monitor: Sernivo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208079 or its brand name (Sernivo, Betamethasone Dipropionate). Reports on generic versions are filed under their own applications.

Reports

6,091

Serious

4,072

67% of reports

Hospitalization

1,820

Death reported

503

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective1,453
  • off label use672
  • macular degeneration532
  • nausea501
  • psoriasis473
  • pruritus468
  • pain451
  • condition aggravated429
  • headache394
  • pain in extremity392
  • rash387
  • fatigue381
  • product use in unapproved indication348
  • dyspnoea341
  • therapeutic product effect incomplete328

Reports by year received

View as table
YearReports
200417
200525
200618
200724
200822
200921
201016
201141
201250
201338
201448
201587
2016167
2017222
2018246
2019354
2020433
2021743
2022738
2023780
2024651
2025756
2026594

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,068 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
macular degenerationSignal532160.9148.180,681
therapeutic product effect incompleteSignal32816.014.44,589
psoriasisSignal47312.511.55,028
condition aggravatedSignal4294.94.51,336
product use in unapproved indicationSignal3484.94.41,072
pain in extremitySignal3924.64.21,115
pruritusSignal4684.23.91,162
drug ineffectiveSignal1,4533.83.63,206
rashSignal3873.12.8548
off label useSignal6722.72.5719
painSignal4512.52.3430
nauseaSignal5012.22.0334
headacheSignal3942.22.0255
dyspnoeaSignal3412.11.9195
fatigue3811.71.5111

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.